Department of Health Services Management, College of Public Health and Health Informatics, Umm Al-Qura University, Makkah, Saudi Arabia.
Department of Preventive Medicine and Public Health Executive, Ministry of Health, Makkah, Saudi Arabia.
Saudi J Kidney Dis Transpl. 2022 Jul-Aug;33(4):516-525. doi: 10.4103/1319-2442.388186.
Despite the evidence that the management of hyperphosphatemia depends heavily on adherence to phosphate-binding (PB) medications, many dialysis patients are non-adherent. Therefore, factors associated with non-adherence to PB medications should be identified and eliminated. This study aimed to identify and highlight factors influencing adherence to PB medications among patients with end-stage kidney disease (ESKD). A cross-sectional survey was conducted in the hemodialysis centers of three major governmental hospitals in Makkah City, Saudi Arabia. The World Health Organization's five dimensions of adherence to medication (patient, socioeconomic, condition, therapy, and health system) were used to guide the analysis. A multivariable logistic regression analysis was used to determine factors influencing adherence to PB medications among patients with ESKD. Three hundred and fifty-eight patients submitted completed questionnaires and were included in this study; of them, 87.99% were adherent to PB medications. The factors sex, adherence to dietary restrictions, and duration on dialysis were found to be significantly and positively associated with adherence to PB medications, whereas the factors difficulty to take medications and difficulty to adhere to a large number of tablets had significant and negative associations with adherence to PB medications. Hyperphosphatemia is a cause for concern as it leads to several life-threatening complications. The results of the present study encourage to recruit representative samples and consider more factors, such as patients' attitudes toward medications and provider-level factors, to inform policy and/or programmatic interventions that increase adherence to PB medications among patients with ESKD.
尽管有证据表明,高磷血症的管理在很大程度上依赖于磷酸盐结合(PB)药物的依从性,但许多透析患者并不依从。因此,应该确定并消除与 PB 药物不依从相关的因素。本研究旨在确定并强调影响终末期肾病(ESKD)患者 PB 药物依从性的因素。在沙特阿拉伯麦加市三家主要政府医院的血液透析中心进行了横断面调查。采用世界卫生组织药物依从性的五个维度(患者、社会经济、病情、治疗和卫生系统)来指导分析。采用多变量逻辑回归分析确定影响 ESKD 患者 PB 药物依从性的因素。358 名患者提交了完整的问卷并被纳入本研究;其中,87.99%的患者依从 PB 药物治疗。研究结果发现,性别、饮食限制的依从性和透析时间这三个因素与 PB 药物的依从性呈显著正相关,而服药困难和难以遵守大量药片这两个因素与 PB 药物的依从性呈显著负相关。高磷血症令人担忧,因为它会导致多种危及生命的并发症。本研究结果鼓励招募有代表性的样本,并考虑更多因素,如患者对药物的态度和提供者层面的因素,为提高 ESKD 患者 PB 药物的依从性提供政策和/或计划干预措施。